From: The association of liver function and quality of life of patients with liver cancer
Variable | N | % | Mean ± SD |
Clinical data | |||
 Age < = 65 | 328 | 69 | 60 ± 12 |
 Male gender | 419 | 89 |  |
ECOG | |||
 0 | 144 | 31 |  |
 1 | 299 | 63 |  |
 ≥ 2 | 29 | 6 |  |
Cirrhosis (radiological) | 278 | 59 | Â |
Tumor morphology | |||
 Uninodular | 122 | 26 |  |
 Multinodular | 143 | 30 |  |
 Diffuse | 207 | 44 |  |
Extrahepatic metastasis (nodal or distant) | 108 | 23 | Â |
Portal vein thrombosis | 152 | 32 | Â |
Hepatitis B surface antigen + | 386 | 82 | Â |
Hepatitis C antibody + | 30 | 6 | Â |
α-feto protein ≥200 mg/ml | 250 | 53 |  |
ALBI score | 472 |  | −2.29 ± 1.33 |
 Grade 1 | 155 | 32.8 |  |
 Grade 2 | 265 | 56.2 |  |
 Grade 3 | 52 | 11.0 |  |
MELD score | 472 |  | 9.08 ± 4.05 |
 Grade 1 (< 10) | 319 | 67.6 |  |
 Grade 2 (10–14) | 109 | 21.4 |  |
 Grade 3 (> 14) | 52 | 11.0 |  |
Child-Pugh class | |||
 A | 319 | 67.6 |  |
 B | 130 | 27.5 |  |
 C | 23 | 4.9 |  |
Albumin | 472 | 100 | 37.4 ± 15.2 |
Bilirubin | 472 | 100 | 32.8 ± 45.7 |
INR | 472 | 100 | 1.15 ± 0.17 |
ALP | 472 | 100 | 193.4 ± 155.8 |
ALT | 472 | 100 | 77.3 ± 69.4 |
Albumin-to-ALP ratio | 472 | 100 | 0.29 ± 0.22 |
ALP-to-platelet ratio | 472 | 100 | 1.20 ± 1.19 |
Presence of ascites | 122 | 25.8 | Â |
Hemoglobin < 10 g/dL | 27 | 6 |  |
White cell count > 10 × 109/L | 64 | 14 |  |
Platelet count < 100 × 109/L | 33 | 7 |  |
1st line Treatment | |||
 Surgical treatment | 54 | 12 |  |
 Local ablative therapies | 29 | 6 |  |
 Trans-arterial therapies | 116 | 25 |  |
 Systemic therapies | 91 | 19 |  |
 Best supportive care alone | 182 | 38 |  |